Hengrui Medicine's HR19003 patch was approved for clinical use

On August 5, Hengrui Pharmaceuticals issued an announcement stating that the company has recently received the "Notice of Drug Clinical Trial Approval" for the HR19003 patch approved by the National Medical Products Administration, agreeing to use this product for post-herpetic neuralgia.

Shingles is a cluster of herpes distributed along the nerves caused by varicella-zoster virus infection

This product can penetrate the skin around the peripheral nerves of the medication site, block the sodium ion channel on the nerve cell membrane, inhibit the flow of sodium ions into the nerve fiber cell membrane, block nerve excitement and conduction, and produce reversible local block, thereby achieving analgesia and anesthesia The effect

After inquiring the EvaluatePharma database, Lidoderm®'s global sales in 2020 are approximately US$345 million, and Ztlido®'s global sales in 2020 are approximately US$26 million.